NCT05926440: Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults |
|
|
| Withdrawn | 3 | 600 | RoW | SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection | Clover Biopharmaceuticals AUS Pty Ltd | COVID-19 | 08/23 | 08/23 | | |
